Omar Kayaleh

599 total citations
15 papers, 457 citations indexed

About

Omar Kayaleh is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Omar Kayaleh has authored 15 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Surgery and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Omar Kayaleh's work include Pancreatic and Hepatic Oncology Research (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Omar Kayaleh is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). Omar Kayaleh collaborates with scholars based in United States, France and Canada. Omar Kayaleh's co-authors include E. Claire Dees, Petr Zatloukal, A. Craig Lockhart, Claudio Dansky Ullmann, Jaafar Bennouna, Bohuslav Melichar, Antoine Adenis, Radka Obermannová, Bin Zhang and Angela DeMichele and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Omar Kayaleh

15 papers receiving 452 citations

Peers

Omar Kayaleh

ONCOL

MB

SURGE

PRM

CB

Masami Mitani Japan

Hanguang Hu China

Mina Waraya Japan

Jiun‐Yi Hsia Taiwan

Mauro Alessandro Scotti Italy

Manoj Shah India

Makiko Yasumoto Japan

Seiichi Fukuyama Japan

Hideki Ushiku Japan

Kaoru Takami Japan

Masami Mitani Japan

Omar Kayaleh

220 ×0.7

ONCOL

262 ×1.6

MB

95 ×0.9

SURGE

98 ×0.9

PRM

26 ×0.3

CB

Citations per year, relative to Omar Kayaleh Omar Kayaleh (= 1×) peers Masami Mitani

Countries citing papers authored by Omar Kayaleh

Since Specialization

Citations

This map shows the geographic impact of Omar Kayaleh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Kayaleh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Kayaleh more than expected).

Fields of papers citing papers by Omar Kayaleh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Kayaleh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Kayaleh. The network helps show where Omar Kayaleh may publish in the future.

Co-authorship network of co-authors of Omar Kayaleh

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Kayaleh. A scholar is included among the top collaborators of Omar Kayaleh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Kayaleh. Omar Kayaleh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

George, Thomas J., Ibrahim Nassour, İlyas Şahin, et al.. (2024). Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).. Journal of Clinical Oncology. 42(3_suppl). 655–655. 1 indexed citations

2.

Lee, Ji‐Hyun, Brian Hemendra Ramnaraign, İlyas Şahin, et al.. (2023). A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Future Oncology. 19(27). 1843–1853. 1 indexed citations

3.

Kayaleh, Omar, et al.. (2020). Hypercalcemia Resulting from Necrotizing Leiomyoma in a Pregnant Female. American Journal of Case Reports. 21. e923412–e923412. 2 indexed citations

4.

Lee, James J., Greg Yothers, Thomas J. George, et al.. (2019). Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9. 2257–2257. 1 indexed citations

5.

Lee, James J., Greg Yothers, Thomas J. George, et al.. (2019). Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9. Cancer Research. 79(13_Supplement). 2257–2257. 2 indexed citations

6.

Cheung, Mitchell, Yuwaraj Kadariya, Jacqueline Talarchek, et al.. (2015). Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene–environment interaction. Cancer Letters. 369(2). 261–265. 33 indexed citations

7.

Melichar, Bohuslav, Antoine Adenis, A. Craig Lockhart, et al.. (2015). Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. The Lancet Oncology. 16(4). 395–405. 200 indexed citations

8.

Sankpal, Umesh T., Steven Goodison, Omar Kayaleh, & Riyaz Basha. (2015). Abstract A03: Tolfenamic acid induces the response of chemotherapy in pancreatic cancer: Preclinical study. Clinical Cancer Research. 21(4_Supplement). A03–A03. 1 indexed citations

9.

Kayaleh, Omar, et al.. (2014). Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review. Archives of Gynecology and Obstetrics. 290(3). 591–594. 16 indexed citations

10.

El-Khoueiry, Anthony B., Cathryn Rankin, Syma Iqbal, et al.. (2014). S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. British Journal of Cancer. 110(4). 882–887. 92 indexed citations

11.

Sankpal, Umesh T., Pius Maliakal, Debashish Bose, et al.. (2012). Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy. Current Medicinal Chemistry. 19(22). 3779–3786. 38 indexed citations

12.

El-Khoueiry, Anthony B., Cathryn Rankin, Syma Iqbal, et al.. (2012). SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma.. Journal of Clinical Oncology. 30(15_suppl). 4113–4113. 4 indexed citations

13.

Ko, Andrew H., Hagop Youssoufian, Jayne Gurtler, et al.. (2011). A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Investigational New Drugs. 30(4). 1597–1606. 49 indexed citations

14.

Brown, Clarence H., Said Baidas, Julio Hajdenberg, et al.. (2009). Lifestyle Interventions in the Prevention and Treatment of Cancer. American Journal of Lifestyle Medicine. 3(5). 337–348. 7 indexed citations

15.

Xiong, Henry Q., Kenneth R. Hess, Omar Kayaleh, et al.. (2005). A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer. Journal of Clinical Oncology. 23(16_suppl). 4174–4174. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact